Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5  (09-2015)

Period of time： 2015年5期

Publisher： John Wiley & Sons Inc

Founded in： 2012

Total resources： 25

E-ISSN： 2160-7648|2160-763X|5

ISSN： 2160-763X

Subject： R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5

Menu

Issue Information

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. i-iv

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Developing antisense oligonucleotide and short‐interfering RNA therapeutics – a few considerations

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 323-325

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 326-336

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Inhibition of prostacyclin and thromboxane biosynthesis in healthy volunteers by single and multiple doses of acetaminophen and indomethacin

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 337-345

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Single‐dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 346-353

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 354-360

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Single‐ and multiple‐dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended‐release oxycodone with sequestered naltrexone 40 mg twice daily to oxycontin 40 mg twice daily and extended‐release oxycodone with sequestered naltrexone 80 mg once daily

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 361-369

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO‐02, an extended release formulation of oxycodone with sequestered naltrexone

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 370-376

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open‐label, crossover phase 1 study

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 377-386

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment

Clinical Pharmacology In Drug Development,volume 2160-763X,issue 5 , Vol. 2160-763X, Iss. 5, 2015-09 , pp. 387-394

John Wiley & Sons Inc

Abstract Access to resources Recommend Favorite

Previous 1 2 Next Display item(s) per page Total 11 item(s)